Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group
Neuro-Oncology · 05.09.2023 · 25 (9) · 1672-1685
DOI: 10.1093/neuonc/noad074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 30.05.2023. Verfasst von Philipp Karschnia und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
The value of re-resection in recurrent glioblastoma remains controversial as a randomized trial that specifies intentional incomplete resection cannot be justified ethically. Here, we aimed to (1) explore the prognostic role of extent of re-resection using the previously proposed Response Assessment in Neuro-Oncology (RANO) classification (based upon residual contrast-enhancing (CE) and non-CE tumor), and to (2) define factors consolidating the surgical effects on outcome.
Methods
The RANO resect group retrospectively compiled an 8-center cohort of patients with first recurrence from previously resected glioblastomas. The associations of re-resection and other clinical factors with outcome were analyzed. Propensity score-matched analyses were constructed to minimize confounding effects when comparing the different RANO classes.
Results
We studied 681 patients with first recurrence of Isocitrate Dehydrogenase (IDH) wild-type glioblastomas, including 310 patients who underwent re-resection. Re-resection was associated with prolonged survival even when stratifying for molecular and clinical confounders on multivariate analysis; ≤1 cm3 residual CE tumor was associated with longer survival than non-surgical management. Accordingly, “maximal resection” (class 2) had superior survival compared to “submaximal resection” (class 3). Administration of (radio-)chemotherapy in the absence of postoperative deficits augmented the survival associations of smaller residual CE tumors. Conversely, “supramaximal resection” of non-CE tumor (class 1) was not associated with prolonged survival but was frequently accompanied by postoperative deficits. The prognostic role of residual CE tumor was confirmed in propensity score analyses.
Conclusions
The RANO resect classification serves to stratify patients with re-resection of glioblastoma. Complete resection according to RANO resect classes 1 and 2 is prognostic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany.
- German Cancer Consortium (DKTK), Partner Site Munich, Germany.
- Department of Neurosurgery, McGovern Medical School at UT Health Houston, Houston, Texas, USA.
- Department of Neurosurgery and Division of Neuro-Oncology, University of San Francisco, San Francisco, California, USA.
- Department of Neurosurgery, University of Cologne, Cologne, Germany.
- Department of Neurosurgery, University of Freiburg, Freiburg, Germany.
ORCID-Profile: Philipp Karschnia, Antonio Dono, Francesco Bruno, Michael Weller, Annette M Molinaro, Nitin Tandon, Mitchel S Berger, Yoshua Esquenazi
Förderung
- NCI NIH HHS
Zitieren
APA
Karschnia, P., Dono, A., Young, J. S., Juenger, S. T., Teske, N., Häni, L., Sciortino, T., Mau, C. Y., Bruno, F., Nunez, L., Morshed, R. A., Haddad, A. F., Weller, M., van den Bent, M., Beck, J., Hervey-Jumper, S., Molinaro, A. M., Tandon, N., Rudà, R., …, & Tonn, J. C. (2023). Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group. Neuro-Oncology, 25(9), 1672-1685. https://doi.org/10.1093/neuonc/noad074
Vancouver
Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, et al. Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group. Neuro-Oncology. 2023;25(9):1672-1685. doi:10.1093/neuonc/noad074
BibTeX
@article{Karschnia2023,
author = {Karschnia, Philipp and Dono, Antonio and Young, Jacob S and Juenger, Stephanie T and Teske, Nico and Häni, Levin and Sciortino, Tommaso and Mau, Christine Y and Bruno, Francesco and Nunez, Luis and Morshed, Ramin A and Haddad, Alexander F and Weller, Michael and van den Bent, Martin and Beck, Juergen and Hervey-Jumper, Shawn and Molinaro, Annette M and Tandon, Nitin and Rudà, Roberta and Vogelbaum, Michael A and Bello, Lorenzo and Schnell, Oliver and Grau, Stefan J and Chang, Susan M and Berger, Mitchel S and Esquenazi, Yoshua and Tonn, Joerg-Christian},
title = {Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {9},
pages = {1672--1685},
doi = {10.1093/neuonc/noad074}
}
EUVIMED